Microscopic yeast have been wreaking havoc in hospitals around the world—creeping into catheters, ventilator tubes, and IV lines—and causing deadly invasive infection. One culprit species, Candida auris, is resistant to many antifungals, meaning once a person is infected, there are limited treatment options. But in a recent Antimicrobial Agents and Chemotherapy study, researchers confirmed a new drug compound kills drug-resistant C. auris, both in the laboratory and in a mouse model that mimics human infection.
APX001, the prodrug of the active moiety APX001A, is currently in clinical development by Amplyx Pharmaceuticals. It works through a novel mechanism of action. Unlike other antifungal agents that poke holes in yeast cell membranes or inhibit sterol synthesis, the new drug targets an enzyme called Gwt1, which is required for anchoring critical proteins to the fungal cell wall. This means C. auris can’t grow properly and has a harder time forming drug-resistant fungal biofilms that are a stubborn source of hospital outbreaks. Gwt1 is highly conserved across fungal species, suggesting the new drug could treat a broad range of fungal infections.
“The drug is first in a new class of antifungals, which could help stave off drug resistance. Even the most troublesome strains are unlikely to have developed workarounds for its mechanism of action,” said study lead Mahmoud A. Ghannoum, PhD, professor of dermatology at Case Western Reserve University School of Medicine and director of the Center for Medical Mycology at Case Western Reserve University and University Hospitals Cleveland Medical Center.
In the new study, Ghannoum’s team tested the drug against 16 different C. auris strains, collected from infected patients in Germany, Japan, South Korea, and India. When they exposed the isolates to the new drug, they found it more potent than nine other currently available antifungals. According to the authors, the concentration of study drug needed to kill C. auris growing in laboratory dishes was “eight-fold lower than the next most active drug, anidulafungin, and more than 30-fold lower than all other compounds tested.”
The researchers also developed a new mouse model of invasive C. auris infection for the study. Said Ghannoum, “To help the discovery of effective drugs it will be necessary to have an animal model that mimics this infection. Our work helps this process in two ways: first we developed the needed animal model that mimics the infection caused by this devastating yeast, and second, we used the developed model to show the drug is effective in treating this infection.”
Ghannoum studied immunocompromised mice infected with C. auris via their tail vein—similar to very sick humans in hospitals who experience bloodstream infections. Infected mice treated with APX001 and anidulafungin had significant reductions in kidney and lung fungal burden two days post-treatment, compared to control animals. APX001 also significantly decreased fungal burden in the brain, consistent with brain penetration, whereas reduction with anidulafungin did not reach significance. The results suggest the new drug could help treat even the most invasive infections.
According to Ghannoum, the most exciting element of the study is that it brings a promising antifungal one step closer to patients. It helps lay the foundation for phase 2 clinical trials that study that study the safety and efficacy of new drugs in patients with fungal infections. There is an urgent need for such studies, as C. auris infection has become a serious threat to healthcare facilities worldwide—and resistance to commercially available antifungal drugs is rising.
“Limited treatment options calls for the development of new drugs that are effective against this devastating infection,” Ghannoum said. “We hope that we contributed in some way towards the development of new drugs.”
The Latest on: Antifungal
- Cidara Therapeutics to Present Data on Lead Antifungal Rezafungin at IDWeek 2018 on September 13, 2018 at 3:55 am
SAN DIEGO--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data demonstrating ... […]
- Antifungal Drug Market 2018: Global Key Players, Trends, Share, Industry Size, Segmentation, Opportunities, Forecast To 2025 on September 7, 2018 at 2:20 am
This report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. This report studies ... […]
- Antifungal Drug Market 2018: Global Key Players, Trends, Share, Industry Size, Segmentation, Opportunities, Forecast To 2025 on September 7, 2018 at 12:20 am
This report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. This report studies the gl... […]
- Antifungal Drug Market 2018: Global Key Players, Trends, Share, Industry Size, Segmentation, Opportunities, Forecast To 2025 on September 6, 2018 at 11:50 pm
“Antifungal Drug”This report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. This repo... […]
- Pediatric Antibacterial and Antifungal Trials From 2007 to 2017 on August 29, 2018 at 5:59 am
BACKGROUND AND OBJECTIVES: The impact of the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) on pediatric antibacterial or antifungal drug trials is unknown. ... […]
- New antifungal provides hope in fight against superbugs on January 11, 2018 at 4:00 pm
Candida albicans, which is related to Candida auris. Credit: CDC The drug is first in a new class of antifungals, which could help stave off drug resistance. Even the most troublesome strains are unli... […]
- 2018 Could Be Hallmark Year For These Two Antifungal Companies on January 8, 2018 at 12:27 pm
A pair drug companies are undergoing clinical trials in hopes of receiving approval from the Food and Drug Administration for getting their antifungal medicines in front of the public in 2018. If they ... […]
- Nigeria: Paediatrician Warns Against Using Antifungal As Body Cream on July 11, 2017 at 7:42 am
An Ilorin based paediatrician, Dr Khadijat Ajadi has warned against the use of antifungal creams mixed with baby body creams to bleach the skin of their babies. Ajadi told Newsmen on Tuesday in Ilorin ... […]
via Google News and Bing News